Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Old Diabetes Drug Teaches Experts New Tricks
Research from the Johns Hopkins Children"s Center reveals that the drug most commonly used in type 2 diabetics who don"t need insulin works on a much more basic level than once thought, treating persistently elevated blood sugar - the hallmark of type 2 diabetes - by regulating the genes that control its production.
generic viagra online
How To Text Message And Avoid Pain
While it is well known that excessive text messaging can result in sore thumbs, less is known about its possible effects on the neck, arms and hands. Young adults with symptoms in these parts of the body use a different technique when texting, according to a study at the Sahlgrenska Academy, University of Gothenburg, Sweden.
News of the day
Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus(R) In Head-to-Head DURATION-3 Study
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results from a study comparing subjects randomized to either exenatide once weekly or Lantus® (insulin glargine). Patients randomized to exenatide once weekly experienced a statistically superior reduction in A1C, a measure of average blood sugar over three months, of 1.5 percentage points from baseline, compared to a reduction of 1.3 percentage points for Lantus after completing 26 weeks of treatment. At the end of the study, patients treated with exenatide once weekly achieved a mean A1C of 6.8 percent compared with a mean A1C of 7.0 percent in those treated with Lantus. Treatment with exenatide once weekly also produced a statistically significant difference in weight, with a mean weight loss of 5.8 pounds at 26 weeks, compared with a mean weight gain of 3.1 pounds for Lantus, a difference of 8.9 pounds between the treatments.
Health Insurance

Enzyme Important In Aging Identified By Scientists At Children's Hospital Of Pittsburgh Of UPMC

The secret to longevity may lie in an enzyme with the ability to promote a robust immune system into old age by maintaining the function of the thymus throughout life, according to researchers studying an "anti-aging" mouse model that lives longer than a typical mouse. The study, led by Abbe de Vallejo, Ph.D., associate professor of pediatrics and immunology, University of Pittsburgh School of Medicine, and immunologist at Children"s Hospital of Pittsburgh of UPMC, reports that the novel mouse model has a thymus that remains intact throughout its life. In all mammals, the thymus - the organ that produces T cells to fight disease and infection - degenerates with age. Results of the study are published in this week"s issue of the Proceedings of the National Academy of Sciences. "These findings give us hope that we may one day have the ability to restore the function of the thymus in old age, or perhaps by intervening at an early age, we may be able to delay or even prevent the degeneration of the thymus in order to maintain our immune defenses throughout life," said Dr. de Vallejo. The mouse model that Dr. de Vallejo"s team studied was developed by his colleague Cheryl Conover, Ph.D., an endocrinology researcher at Mayo Clinic. In this "knockout" mouse model, researchers deleted an enzyme known as pregnancy-associated plasma protein A (PAPPA). PAPPA-knockout mice live at least 30 percent longer and have significantly lower occurrence of spontaneous tumors than typical mice. PAPPA controls the availability in tissues of a hormone known as insulin-like growth factor (IGF) that is a promoter of cell division. Hence, IGF is required for normal embryonic and postnatal growth. But IGF also is associated with tumor growth, inflammation and cardiovascular disease in adults. By deleting PAPPA, the researchers were able to control the availability of IGF in tissues and dampen its many ill effects. In the thymus, deletion of PAPPA maintained just enough IGF to sustain production of T cells without consuming precursor cells, thereby preventing the degeneration of the thymus. "Controlling the availability of IGF in the thymus by targeted manipulation of PAPPA could be a way to maintain immune protection throughout life," Dr. de Vallejo said. "This study has profound implications for the future study of healthy aging and longevity." Marc Lukasiak University of Pittsburgh Schools of the Health Sciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009